合成生物学助力细菌疫苗研发

章金勇; 顾江; 关山; 李海波; 曾浩; 邹全明

doi:10.12211/2096-8280.2023-070

您当前的位置：

首页 >

文章列表页 >

合成生物学助力细菌疫苗研发

特约评述 | 更新时间：2025-03-20

- 合成生物学助力细菌疫苗研发
- Synthetic biology promotes the development of bacterial vaccines
- 合成生物学 2024年5卷第2期页码：321-337
- 作者机构：
  
  陆军军医大学国家免疫生物制品工程技术研究中心，陆军军医大学药学与检验医学系微生物与生化药学教研室，重庆 400037
- 作者简介：
  
  [ "章金勇（1982—），男，博士，教授。研究方向为病原体致病机制与免疫防治。E-mail：zhangjy198217@126.com" ]
  [ "邹全明（1963—），男，博士，教授。研究方向为超级细菌感染与创新疫苗研发。E-mail：qmzou2007@163.com" ]
- 基金信息：
  
  国家自然科学基金青年科学基金(32170938)
- DOI：10.12211/2096-8280.2023-070
  中图分类号： Q819
- 收稿：2023-10-07，
  
  修回：2023-12-05，
  
  纸质出版：2024-04-30
- 稿件说明：
移动端阅览
章金勇，顾江，关山，李海波，曾浩，邹全明. 合成生物学助力细菌疫苗研发［J］. 合成生物学， 2024， 5（2）： 321-337

ZHANG Jinyong， GU Jiang， GUAN Shan， LI Haibo， ZENG Hao， ZOU Quanming. Synthetic biology promotes the development of bacterial vaccines［J］. Synthetic Biology Journal， 2024， 5（2）： 321-337
章金勇，顾江，关山，李海波，曾浩，邹全明. 合成生物学助力细菌疫苗研发［J］. 合成生物学， 2024， 5（2）： 321-337 DOI： 10.12211/2096-8280.2023-070.

ZHANG Jinyong， GU Jiang， GUAN Shan， LI Haibo， ZENG Hao， ZOU Quanming. Synthetic biology promotes the development of bacterial vaccines［J］. Synthetic Biology Journal， 2024， 5（2）： 321-337 DOI： 10.12211/2096-8280.2023-070.

摘要

细菌感染已成为全球第二大死亡因素，给人类健康与公共安全造成了巨大威胁。抗生素一直是治疗细菌感染最为主要的手段，但越来越严重的耐药问题给传统的抗生素疗法带来了严峻挑战。除了抗生素之外，疫苗被认为是防治传染性疾病传播最为科学、经济、安全和有效的手段，在人类抗击病原体感染斗争中发挥了重要作用。然而，细菌基因组庞大，致病机制复杂，研发疫苗存在有效抗原筛选、设计、制备难，抗原组合配伍难，有效性评价难，研发周期长等诸多瓶颈，导致细菌疫苗研发进展缓慢，尤其是临床常见的严重耐药致病菌尚无有效的疫苗可用。合成生物学是一门新兴的交叉学科，近年来在疫苗研究领域已经得到了广泛应用，包括抗原的筛选、理性设计、配伍组合，载体、佐剂和递送系统的设计以及免疫应答调控等。本文综述了细菌疫苗研究的现状以及耐药细菌疫苗临床试验研究进展，总结了合成生物学技术在几种重要类型细菌疫苗研发中的应用进展，最后对相关前景进行了展望。合成生物学在疫苗的形式、疫苗递送、疫苗的研制效率等方面为研究人员提供了更为广阔的空间，未来，应最大化地发挥合成生物学的优势，充分发展和应用合成生物学技术手段，建立科学、理性、有效、可行的管理制度，建设生物安全保障法律体系和监管措施，高效推动细菌疫苗研发，解决抗生素耐药问题，造福人类健康。

Abstract

In recent years

bacterial infections have emerged as the second leading cause of death globally

posing a serious threat to public health and demanding prioritized intervention from the healthcare community worldwide. While antibiotics have conventionally been used as the primary strategy to combat bacterial infections

their efficacy is increasingly compromised due to the emergence of drug-resistant bacteria

especially multi-drug-resistant and even pan-drug-resistant superbacteria. Vaccines are thus considered as one of the most scientific

economical

safe

and effective means to prevent infectious diseases and improve public health

which are estimated to save 2 to 3 million lives annually

and can serve as a critical tool in the battle against an

timicrobial resistance. However

the complexity of bacterial structure and pathogenic mechanism has hindered the development of vaccines. Challenges include screening and rationally design of effective antigens

ensuring compatibility of various antigen combinations

establishing animal models for preclinical evaluation

and defining reliable endpoints for clinical efficacy assessment. As a result

only a small number of bacteria vaccines have been successfully developed so far

and none of them has been licensed to combat the most prevalent drug-resistant infections

such as

Staphylococcus aureus

Acinetobacter baumannii

Pseudomonas aeruginosa

and

Klebsiella pneumoniae

. Synthetic biology is a brand-new multidisciplinary focusing on repurposing natural biological systems and inventing innovative biological tools

technologies

devices

and systems for practical applications

and its concepts

principles and technologies have been extensively employed to facilitate vaccine development

including rational design

screening

and optimization of antigen

carrier

adjuvant and delivery system as well as the modulation of bacterial pathogenicity and immune responses. Herein

we outline the current status of the development of bacterial vaccines and the advancement of clinical trials for drug-resistant bacterial vaccines. Then

we summarize the application of synthetic biology technology in the development of major bacterial vaccines. Finally

we prospect the potential of synthetic biology in creating novel bacterial vaccines. Researchers have access to a greater variety of design possibilities for bacterial vaccines through synthetic biology. To maximize these benefits

we should employ synthetic biology and related technologies more efficiently in developing bacterial vaccines. Meanwhile

we should develop a scientific

reasonable

effective

and feasible management system

as well as regulatory measures

to expedite the development of efficient bact

erial vaccines

therefore addressing the problem of antibiotic resistance to protect human health.

关键词

Keywords

references

COOK M A , WRIGHT G D . The past, present, and future of antibiotics [J ] . Science Translational Medicine , 2022 , 14 ( 657 ): eabo7793 .

GBD 2019 Diseases and Injuries Collaborators . Global burden of 369 diseases and injuries in 204 countries and territories, 1990—2019: a systematic analysis for the Global Burden of Disease Study 2019 [J ] . The Lancet , 2020 , 396 ( 10258 ): 1204 - 1222 .

SULIS G , SAYOOD S , KATUKOORI S , et al . Exposure to World Health Organization’s aware antibiotics and isolation of multidrug resistant bacteria: a systematic review and meta-analysis [J ] . Clinical Microbiology and Infection , 2022 , 28 ( 9 ): 1193 - 1202 .

GBD 2019 Antimicrobial Resistance Collaborators . Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019 [J ] . The Lancet , 2022 , 400 ( 10369 ): 2221 - 2248 .

Antimicrobial Resistance Collaborators . Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis [J ] . The Lancet , 2022 , 399 ( 10325 ): 629 - 655 .

FERRI M , RANUCCI E , ROMAGNOLI P , et al . Antimicrobial resistance: a global emerging threat to public health systems [J ] . Critical Reviews in Food Science and Nutrition , 2017 , 57 ( 13 ): 2857 - 2876 .

ZHANG Y D , LI M , DU G S , et al . Advancedoral vaccine delivery strategies for improving the immunity [J ] . Advanced Drug Delivery Reviews , 2021 , 177 : 113928 .

MICOLI F , BAGNOLI F , RAPPUOLI R , et al . The role of vaccines in combatting antimicrobial resistance [J ] . Nature Reviews Microbiology , 2021 , 19 ( 5 ): 287 - 302 .

赵国屏 . 合成生物学: 从“造物致用”到产业转化 [J ] . 生物工程学报 , 2022 , 38 ( 11 ): 4001 - 4011 .

ZHAO G P . Synthetic biology: from “build-for-use” to commercialization [J ] . Chinese Journal of Biotechnology , 2022 , 38 ( 11 ): 4001 - 4011 .

宋斐 , 蔡志明 , 黄卫人 . 合成生物开启生物医药崭新篇章: 预防、诊断与治疗 [J ] . 合成生物学 , 2023 , 4 ( 2 ): 241 - 243 .

SONG F , CAI Z M , HUANG W R . Synthetic biology opens a new chapter in biomedicine: prevention, diagnosis and treatment [J ] . Synthetic Biology Journal , 2023 , 4 ( 2 ): 241 - 243 .

邹全明 , 曾浩 . 超级细菌疫苗研究的挑战与策略 [J ] . 第三军医大学学报 , 2019 , 41 ( 19 ): 1823 - 1825, 1827 .

ZOU Q M , ZENG H . Development of vaccines against superbugs: challenges and strategies [J ] . Journal of Third Military Medical University , 2019 , 41 ( 19 ): 1823 - 1825, 1827 .

FROST I , SATI H , GARCIA-VELLO P , et al . The role of bacterial vaccines in the fight against antimicrobial resistance: an analysis of the preclinical and clinical development pipeline [J ] . The Lancet Microbe , 2023 , 4 ( 2 ): e113 - e125 .

JIANG X Y , GONG M Q , ZHANG H J , et al . The safety and immunogenicity of a recombinant five-antigen Staphylococcus aureus vaccine among patients undergoing elective surgery for closed fractures: a randomized, double-blind, placebo-controlled, multicenter phase 2 clinical trial [J ] . Vaccine , 2023 , 41 ( 38 ): 5562 - 5571 .

HASSANZADEH H , BABER J , BEGIER E , et al . Efficacy of a 4-antigen Staphylococcus aureus vaccine in spinal surgery: the Staphylococcus aureus surgical inpatient vaccine efficacy (STRIVE) randomized clinical trial [J ] . Clinical Infectious Diseases , 2023 , 77 ( 2 ): 312 - 320 .

LANDRUM M L , LALANI T , NIKNIAN M , et al . Safety and immunogenicity of a recombinant Staphylococcus aureus α-toxoid and a recombinant Panton-Valentine leukocidin subunit, in healthy adults [J ] . Human Vaccines & Immunotherapeutics , 2017 , 13 ( 4 ): 791 - 801 .

XU Q F , PRYHARSKI K , PICHICHERO M E . Trivalent pneumococcal protein vaccine protects against experimental acute otitis media caused by Streptococcus pneumoniae in an infant murine model [J ] . Vaccine , 2017 , 35 ( 2 ): 337 - 344 .

MOFFITT K , MALLEY R . Rationale and prospects for novel pneumococcal vaccines [J ] . Human Vaccines & Immunotherapeutics , 2016 , 12 ( 2 ): 383 - 392 .

SCHMID P , SELAK S , KELLER M , et al . Th17/Th1 biased immunity to the pneumococcal proteins PcsB, StkP and PsaA in adults of different age [J ] . Vaccine , 2011 , 29 ( 23 ): 3982 - 3989 .

SULIMAN S , LUABEYA A K K , GELDENHUYS H , et al . Dose optimization of H56: IC31 vaccine for tuberculosis-endemic populations. A double-blind, placebo-controlled, dose-selection trial [J ] . American Journal of Respiratory and Critical Care Medicine , 2019 , 199 ( 2 ): 220 - 231 .

PENN-NICHOLSON A , TAMERIS M , SMIT E , et al . Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial [J ] . The Lancet Respiratory Medicine , 2018 , 6 ( 4 ): 287 - 298 .

TKACHUK A P , BYKONIA E N , POPOVA L I , et al . Safety and immunogenicity of the GamTBvac, the recombinant subunit tuberculosis vaccine candidate: a phase Ⅱ, multi-center, double-blind, randomized, placebo-controlled study [J ] . Vaccines , 2020 , 8 ( 4 ): 652 .

ADLBRECHT C , WURM R , DEPUYDT P , et al . Efficacy, immunogenicity, and safety of IC43 recombinant Pseudomonas aeruginosa vaccine in mechanically ventilated intensive care patients-a randomized clinical trial [J ] . Critical Care , 2020 , 24 ( 1 ): 74 .

BREWER S M , BRUBAKER S W , MONACK D M . Host inflammasome defense mechanisms and bacterial pathogen evasion strategies [J ] . Current Opinion in Immunology , 2019 , 60 : 63 - 70 .

MASKELL D , FRANKEL G , DOUGAN G . Phase and antigenic variation—the impact on strategies for bacterial vaccine design [J ] . Trends in Biotechnology , 1993 , 11 ( 12 ): 506 - 510 .

LAMBERTI Y , SURMANN K . The intracellular phase of extracellular respiratory tract bacterial pathogens and its role on pathogen-host interactions during infection [J ] . Current Opinion in Infectious Diseases , 2021 , 34 ( 3 ): 197 - 205 .

BJÖRKSTÉN B . Diverse microbial exposure - consequences for vaccine development [J ] . Vaccine , 2012 , 30 ( 29 ): 4336 - 4340 .

邹全明 , 石云 . 超级细菌疫苗研究进展 [J ] . 第三军医大学学报 , 2016 , 38 ( 7 ): 663 - 668 .

ZOU Q M , SHI Y . Prospect for vaccines to prevent superbug infection [J ] . Journal of Third Military Medical University , 2016 , 38 ( 7 ): 663 - 668 .

SAKURAI F , TACHIBANA M , MIZUGUCHI H . Adenovirus vector-based vaccine for infectious diseases [J ] . Drug Metabolism and Pharmacokinetics , 2022 , 42 : 100432 .

TAN X , LETENDRE J H , COLLINS J J , et al . Synthetic biology in the clinic: engineering vaccines, diagnostics, and therapeutics [J ] . Cell , 2021 , 184 ( 4 ): 881 - 898 .

VOLPEDO G , BHATTACHARYA P , GANNAVARAM S , et al . The history of live attenuated Centrin gene-deleted Leishmania vaccine candidates [J ] . Pathogens , 2022 , 11 ( 4 ): 431 .

冯生 , 刘宝山 , 陈泽良 , 等 . 布鲁菌基因缺失疫苗侯选株研究进展 [J ] . 动物医学进展 , 2020 , 41 ( 3 ): 110 - 113 .

FENG S , LIU B S , CHEN Z L , et al . Progress on Brucella gene deletion vaccine strains [J ] . Progress in Veterinary Medicine , 2020 , 41 ( 3 ): 110 - 113 .

PRIEBE G P , BRINIG M M , HATANO K , et al . Construction and characterization of a live, attenuated aroA deletion mutant of Pseudomonas aeruginosa as a candidate intranasal vaccine [J ] . Infection and Immunity , 2002 , 70 ( 3 ): 1507 - 1517 .

JINEK M , CHYLINSKI K , FONFARA I , et al . A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity [J ] . Science , 2012 , 337 ( 6096 ): 816 - 821 .

BHUJBAL S , BHUJBAL R , GIRAM P . An overview: CRISPR/Cas-based gene editing for viral vaccine development [J ] . Expert Review of Vaccines , 2022 , 21 ( 11 ): 1581 - 1593 .

ZHANG W W , KARMAKAR S , GANNAVARAM S , et al . A second generation leishmanization vaccine with a markerless attenuated Leishmania major strain using CRISPR gene editing [J ] . Nature Communications , 2020 , 11 : 3461 .

ATASOY M O , ROHAIM M A , MUNIR M . Simultaneous deletion of virulence factors and insertion of antigens into the infectious laryngotracheitis virus using NHEJ-CRISPR/Cas9 and Cre-Lox system for construction of a stable vaccine vector [J ] . Vaccines , 2019 , 7 ( 4 ): 207 .

TONG X L , FU M Y , CHEN P , et al . Ultrabithorax and abdominal-A specify the abdominal appendage in a dosage-dependent manner in silkworm, Bombyx mori [J ] . Heredity , 2017 , 118 ( 6 ): 578 - 584 .

JEONG S H , LEE H J , LEE S J . Recent advances in CRISPR-Cas technologies for synthetic biology [J ] . Journal of Microbiology , 2023 , 61 ( 1 ): 13 - 36 .

GARST A D , BASSALO M C , PINES G , et al . Genome-wide mapping of mutations at single-nucleotide resolution for protein, metabolic and genome engineering [J ] . Nature Biotechnology , 2017 , 35 ( 1 ): 48 - 55 .

PACHECO A R , LAZARUS J E , SIT B , et al . CRISPR screen reveals that EHEC′s T3SS and shiga toxin rely on shared host factors for infection [J ] . mBio , 2018 , 9 ( 3 ): e01003 - e01018 .

GUTIÉRREZ-ORTEGA A , MORENO D A , FERRARI S A , et al . High-yield production of major T-cell ESAT6-CFP10 fusion antigen of M. tuberculosis complex employing codon-optimized synthetic gene [J ] . International Journal of Biological Macromolecules , 2021 , 171 : 82 - 88 .

孙鹏 , 朱爱臣 , 梁天 , 等 . 鸡IL-17基因的克隆、序列分析及密码子优化提高表达水平 [J ] . 农业生物技术学报 , 2023 , 31 ( 7 ): 1464 - 1476 .

SUN P , ZHU A C , LIANG T , et al . Cloning, sequence analysis and codon optimization of chicken (gallus gallus) IL-17 gene to improve the expression level [J ] . Journal of Agricultural Biotechnology , 2023 , 31 ( 7 ): 1464 - 1476 .

CHEN Z F , GOU Q , XIONG Q S , et al . Immunodominance of epitopes and protective efficacy of HI antigen are differentially altered using different adjuvants in a mouse model of Staphylococcus aureus bacteremia [J ] . Frontiers in Immunology , 2021 , 12 : 684823 .

YANG F , GU J , YANG L Y , et al . Protective efficacy of the trivalent Pseudomonas aeruginosa vaccine candidate PcrV-OprI-Hcp1 in murine pneumonia and burn models [J ] . Scientific Reports , 2017 , 7 : 3957 .

CARADONNA T M , SCHMIDT A G . Protein engineering strategies for rational immunogen design [J ] . NPJ Vaccines , 2021 , 6 : 154 .

BENNE N , VAN DUIJN J , KUIPER J , et al . Orchestrating immune responses: how size, shape and rigidity affect the immunogenicity of particulate vaccines [J ] . Journal of Controlled Release , 2016 , 234 : 124 - 134 .

CHARLTON HUME H K , VIDIGAL J , CARRONDO M J T , et al . Synthetic biology for bioengineering virus-like particle vaccines [J ] . Biotechnology and Bioengineering , 2019 , 116 ( 4 ): 919 - 935 .

JOYNER J A , DALY S M , PEABODY J , et al . Vaccination with VLPs presenting a linear neutralizing domain of S. aureus Hla elicits protective immunity [J ] . Toxins , 2020 , 12 ( 7 ): 450 .

JING H M , ZHANG X L , ZOU J T , et al . Oligomerization of IC43 resulted in improved immunogenicity and protective efficacy against Pseudomonas aeruginosa lung infection [J ] . International Journal of Biological Macromolecules , 2020 , 159 : 174 - 182 .

LI Y H , PU R X , ZHANG Y , et al . Self-assembled ferritin nanoparticles displaying PcrV and OprI as an adjuvant-free Pseudomonas aeruginosa vaccine [J ] . Frontiers in Immunology , 2023 , 14 : 1184863 .

ZOU J T , JING H M , YUAN Y , et al . Pore-forming alpha-hemolysin efficiently improves the immunogenicity and protective efficacy of protein antigens [J ] . PLoS Pathogens , 2021 , 17 ( 7 ): e1009752 .

MEHTA N K , PRADHAN R V , SOLEIMANY A P , et al . Pharmacokinetic tuning of protein-antigen fusions enhances the immunogenicity of T-cell vaccines [J ] . Nature Biomedical Engineering , 2020 , 4 ( 6 ): 636 - 648 .

ASSONI L , GIRARDELLO R , CONVERSO T R , et al . Current stage in the development of Klebsiella pneumoniae vaccines [J ] . Infectious Diseases and Therapy , 2021 , 10 ( 4 ): 2157 - 2175 .

VAN DER PUT R M F , METZ B , PIETERS R J . Carriers and antigens: new developments in glycoconjugate vaccines [J ] . Vaccines , 2023 , 11 ( 2 ): 219 .

程亚慧 , 沈荣 , 乔瑞洁 . 细菌性多糖蛋白结合疫苗免疫应答机制的研究进展 [J ] . 微生物学免疫学进展 , 2018 , 46 ( 4 ): 81 - 86 .

CHENG Y H , SHEN R , QIAO R J . Advances on immune response mechanisms of bacterial glyco-conjugate vaccines [J ] . Progress in Microbiology and Immunology , 2018 , 46 ( 4 ): 81 - 86 .

叶精勤 , 黄文华 , 潘超 , 等 . 合成生物学在多糖结合疫苗研发中的应用 [J ] . 合成生物学 , 2024 , 5 ( 2 ): 338 - 352 .

YE J Q , HUANG W H , PAN C , et al . Application of synthetic biology in the development of polysaccharide conjugate vaccines [J ] . Synthetic Biology Journal , 2024 , 5 ( 2 ): 338 - 352 .

KAY E , CUCCUI J , WREN B W . Recent advances in the production of recombinant glycoconjugate vaccines [J ] . NPJ Vaccines , 2019 , 4 : 16 .

HARDING C M , NASR M A , SCOTT N E , et al . A platform for glycoengineering a polyvalent pneumococcal bioconjugate vaccine using E. coli as a host [J ] . Nature Communications , 2019 , 10 : 891 .

FELDMAN M F , MAYER BRIDWELL A E , SCOTT N E , et al . A promising bioconjugate vaccine against hypervirulent Klebsiella pneumoniae [J ] . Proceedings of the National Academy of Sciences of the United States of America , 2019 , 116 ( 37 ): 18655 - 18663 .

彭哲慧 , 潘超 , 孙鹏 , 等 . 生物法合成伤寒O-糖蛋白结合疫苗及其免疫原性评估 [J ] . 遗传 , 2015 , 37 ( 5 ): 473 - 479 .

PENG Z H , PAN C , SUN P , et al . Preparation and immunogenicity-evaluation of typhoid O-specific polysaccharides bio-conjugate vaccines [J ] . Hereditas , 2015 , 37 ( 5 ): 473 - 479 .

SU H L , LIU Q , BIAN X P , et al . Synthesis and delivery of Streptococcus pneumoniae capsular polysaccharides by recombinant attenuated Salmonella vaccines [J ] . Proceedings of the National Academy of Sciences of the United States of America , 2021 , 118 ( 2 ): e2013350118 .

RIDDLE M S , KAMINSKI R W , DI PAOLO C , et al . Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella flexneri 2a administered to healthy adults: a single-blind, randomized phase I study [J ] . Clinical and Vaccine Immunology: CVI , 2016 , 23 ( 12 ): 908 - 917 .

HUTTNER A , HATZ C , VAN DEN DOBBELSTEEN G , et al . Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial [J ] . The Lancet Infectious Diseases , 2017 , 17 ( 5 ): 528 - 537 .

PARDI N , HOGAN M J , PORTER F W , et al . mRNA vaccines — a new era in vaccinology [J ] . Nature Reviews Drug Discovery , 2018 , 17 ( 4 ): 261 - 279 .

龚方苑 . DNA疫苗与mRNA疫苗: 对抗人类疾病的两把利器 [J ] . 张江科技评论 , 2023 ( 3 ): 37 - 39 .

GONG F Y . DNA vaccine and mRNA vaccine: two powerful tools against human diseases [J ] . Zhangjiang Technology Review , 2023 ( 3 ): 37 - 39 .

刘畅 , 邹全明 , 李海波 . 新冠病毒DNA疫苗的研究现状及展望 [J ] . 免疫学杂志 , 2022 , 38 ( 8 ): 726 - 732 .

LIU C , ZOU Q M , LI H B . Research status and prospects of SARS-CoV-2 DNA vaccines [J ] . Immunological Journal , 2022 , 38 ( 8 ): 726 - 732 .

顾江 , 曾浩 , 邹全明 . 创新细菌疫苗的研究进展及挑战 [J ] . 中国生物制品学杂志 , 2021 , 34 ( 9 ): 1017 - 1022 .

GU J , ZENG H , ZOU Q M . Advances and challenges in research on innovative bacterial vaccines [J ] . Chinese Journal of Biologicals , 2021 , 34 ( 9 ): 1017 - 1022 .

NIE X , ZHANG Z , WANG C H , et al . Interactions in DNA condensation: an important factor for improving the efficacy of gene transfection [J ] . Bioconjugate Chemistry , 2019 , 30 ( 2 ): 284 - 292 .

SUN S , LI E T , ZHAO G , et al . Respiratory mucosal vaccination of peptide-poloxamine-DNA nanoparticles provides complete protection against lethal SARS-CoV-2 challenge [J ] . Biomaterials , 2023 , 292 : 121907 .

LIU S L , JIANG Q A , ZHAO X A , et al . A DNA nanodevice-based vaccine for cancer immunotherapy [J ] . Nature Materials , 2021 , 20 ( 3 ): 421 - 430 .

章德广 , 王正敏 , 徐江红 , 等 . 小鼠肺炎链球菌 psaA 核酸疫苗的制备及其初免-蛋白加强免疫策略的研究 [J ] . 中华耳鼻咽喉头颈外科杂志 , 2009 , 44 ( 9 ): 762 - 766 .

ZHANG D G , WANG Z M , XU J H , et al . Improvement of immunogenicity of Streptococcus pneumoniae psaA DNA vaccine by prime and boost strategy [J ] . Chinese Journal of Otorhinolaryngology Head and Neck Surgery , 2009 , 44 ( 9 ): 762 - 766 .

GAUDREAU M C , LACASSE P , TALBOT B G . Protective immune responses to a multi-gene DNA vaccine against Staphylococcus aureus [J ] . Vaccine , 2007 , 25 ( 5 ): 814 - 824 .

GONG Q A , RUAN M D , NIU M F , et al . Immune efficacy of different immunization doses of divalent combination DNA vaccine pOPRL+pOPRF of Pseudomonas aeruginosa [J ] . Journal of Veterinary Medical Science , 2021 , 83 ( 12 ): 1959 - 1964 .

JIANG M Z , YAO J , FENG G Z . Prot ective effect of DNA vaccine encoding Pseudomonas exotoxin A and PcrV against acute pulmonary P. aeruginosa infection [J ] . PLoS One , 2014 , 9 ( 5 ): e96609 .

赵轩 , 江晓烽 , 秦江雷 , 等 . 载铜绿假单胞菌OprF和PcrV基因联合DNA疫苗的水凝胶缓释系统的构建及免疫效力评价 [J ] . 解放军医学杂志 , 2022 , 47 ( 9 ): 871 - 878 .

ZHAO X , JIANG X F , QIN J L , et al . Construction and immune efficacy evaluation of a hydrogel sustained-release system containing a combined DNA vaccine of Pseudomonas aeruginosa OprF and PcrV genes [J ] . Medical Journal of Chinese People’s Liberation Army , 2022 , 47 ( 9 ): 871 - 878 .

AL FAYEZ N , NASSAR M S , ALSHEHRI A A , et al . Recent advancement in mRNA vaccine development and applications [J ] . Pharmaceutics , 2023 , 15 ( 7 ): 1972 .

JIA L F , MAO Y H , JI Q Q , et al . Decoding mRNA translatability and stability from the 5′ UTR [J ] . Nature Structural & Molecular Biology , 2020 , 27 ( 9 ): 814 - 821 .

KARIKÓ K , BUCKSTEIN M , NI H P , et al . Suppression of RNA recognition by toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA [J ] . Immunity , 2005 , 23 ( 2 ): 165 - 175 .

KARIKÓ K , MURAMATSU H , WELSH F A , et al . Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability [J ] . Molecular Therapy , 2008 , 16 ( 11 ): 1833 - 1840 .

ANDRIES O , MCCAFFERTY S , DE SMEDT S C , et al . N 1 -methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice [J ] . Journal of Controlled Release , 2015 , 217 : 337 - 344 .

LI C Y , LIANG Z H , HU Y X , et al . Cytidine-containing tails robustly enhance and prolong protein production of synthetic mRNA in cell and in vivo [J ] . Molecular Therapy - Nucleic Acids , 2022 , 30 : 300 - 310 .

ZHANG H , ZHANG L , LIN A , et al . Algorithm for optimized mRNA design improves stability and immunogenicity [J ] . Nature , 2023 , 621 ( 7978 ): 396 - 403 .

PARDI N , HOGAN M J , WEISSMAN D . Recent advances in mRNA vaccine technology [J ] . Current Opinion in Immunology , 2020 , 65 : 14 - 20 .

MATARAZZO L , BETTENCOURT P J G . mRNA vaccines: a new opportunity for malaria, tuberculosis and HIV [J ] . Frontiers in Immunology , 2023 , 14 : 1172691 .

TERAN-NAVARRO H , SALCINES-CUEVAS D , CALDERON-GONZALEZ R , et al . A comparison between recombinant listeria GAPDH proteins and GAPDH encoding mRNA conjugated to lipids as cross-reactive vaccines for listeria, mycobacterium, and streptococcus [J ] . Frontiers in Immunology , 2021 , 12 : 632304 .

MARUGGI G , CHIAROT E , GIOVANI C , et al . Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens [J ] . Vaccine , 2017 , 35 ( 2 ): 361 - 368 .

WANG X Y , LIU C , RCHEULISHVILI N , et al . Strong immune responses and protection of PcrV and OprF-I mRNA vaccine candidates against Pseudomonas aeruginosa [J ] . NPJ Vaccines , 2023 , 8 : 76 .

KAWAGUCHI K , KINOSHITA M , SUDO K , et al . mRNA vaccine induces protective immunity against the type Ⅲ secretory virulence of Pseudomonas aeruginosa [EB/OL ] . BioRxiv , 2023 : 544431 [ 2023-09-01 ] . https://www.biorxiv.org/content/10.1101/2023.06.09.544431v1 https://www.biorxiv.org/content/10.1101/2023.06.09.544431v1 .

KON E , LEVY Y , ELIA U , et al . A single-dose F1-based mRNA-LNP vaccine provides protection against the lethal plague bacterium [J ] . Science Advances , 2023 , 9 ( 10 ): eadg1036 .

SAJID A , MATIAS J , ARORA G , et al . mRNA vaccination induces tick resistance and prevents transmission of the Lyme disease agent [J ] . Science Translational Medicine , 2021 , 13 ( 620 ): eabj9827 .

PINE M , ARORA G , HART T M , et al . Development of an mRNA-lipid nanoparticle vaccine against Lyme disease [J ] . Molecular Therapy , 2023 , 31 ( 9 ): 2702 - 2714 .

KAPARAKIS-LIASKOS M , FERRERO R L . Immune modulation by bacterial outer membrane vesicles [J ] . Nature Reviews Immunology , 2015 , 15 ( 6 ): 375 - 387 .

ABITBOL V , SOHN W Y , HORN M , et al . Safety and immunogenicity of co-administered meningococcal serogroup B (4CMenB) vaccine: a literature review [J ] . Human Vaccines & Immunotherapeutics , 2023 , 19 ( 2 ): 2245705 .

MARSHALL G S , ABBING-KARAHAGOPIAN V , MARSHALL H S , et al . A comprehensive review of clinical and real-world safety data for the four-component serogroup B meningococcal vaccine (4CMenB) [J ] . Expert Review of Vaccines , 2023 , 22 ( 1 ): 530 - 544 .

SCHWECHHEIMER C , KUEHN M J . Outer-membrane vesicles from gram-negative bacteria: biogenesis and functions [J ] . Nature Reviews Microbiology , 2015 , 13 ( 10 ): 605 - 619 .

姚崧源 , 孙述学 . 细菌外膜囊泡在疫苗领域的研究进展 [J ] . 微生物学免疫学进展 , 2021 , 49 ( 1 ): 78 - 82 .

YAO S Y , SUN S X . Advances in research on bacterial outer membrane vesicles in vaccine [J ] . Progress in Microbiology and Immunology , 2021 , 49 ( 1 ): 78 - 82 .

AASS H C D , HELLUM M , TRØSEID A M S , et al . Whole-blood incubation with the Neisseria meningitidis lpxL1 mutant induces less pro-inflammatory cytokines than the wild type, and IL-10 reduces the MyD88-dependent cytokines [J ] . Innate Immunity , 2018 , 24 ( 2 ): 101 - 111 .

VAN DER LEY P , VAN DEN DOBBELSTEEN G . Next-generation outer membrane vesicle vaccines against Neisseria meningitidis based on nontoxic LPS mutants [J ] . Human Vaccines , 2011 , 7 ( 8 ): 886 - 890 .

FRIRDICH E , WHITFIELD C . Review: Lipopolysaccharide inner core oligosaccharide structure and outer membrane stability in human pathogens belonging to the Enterobacteriaceae [J ] . Journal of Endotoxin Research , 2005 , 11 ( 3 ): 133 - 144 .

LI P , WANG X R , SUN X W , et al . Recombinant Pseudomonas bionanoparticles induce protection against pneumonic Pseudomonas aeruginosa infection [J ] . Infection and Immunity , 2021 , 89 ( 11 ): e00396-21 .

易洁 , 刘青 , 孔庆科 . 革兰氏阴性菌外膜囊泡作为亚单位疫苗的研究进展 [J ] . 微生物学报 , 2016 , 56 ( 6 ): 911 - 921 .

YI J , LIU Q , KONG Q K . Advances in outer membrane vesicles of gram-negative bacteria as sub-unit vaccines - a review [J ] . Acta Microbiologica Sinica , 2016 , 56 ( 6 ): 911 - 921 .

DEATHERAGE B L , LARA J C , BERGSBAKEN T , et al . Biogenesis of bacterial membrane vesicles [J ] . Molecular Microbiology , 2009 , 72 ( 6 ): 1395 - 1407 .

ARIGITA C , JISKOOT W , WESTDIJK J , et al . Stability of mono- and trivalent meningococcal outer membrane vesicle vaccines [J ] . Vaccine , 2004 , 22 ( 5/6 ): 629 - 642 .

SCHWECHHEIMER C , RODRIGUEZ D L , KUEHN M J . NlpI-mediated modulation of outer membrane vesicle production through peptidoglycan dynamics in Escherichia coli [J ] . MicrobiologyOpen , 2015 , 4 ( 3 ): 375 - 389 .

GNOPO Y M D , WATKINS H C , STEVENSON T C , et al . Designer outer membrane vesicles as immunomodulatory systems - reprogramming bacteria for vaccine delivery [J ] . Advanced Drug Delivery Reviews , 2017 , 114 : 132 - 142 .

CHEN D J , OSTERRIEDER N , METZGER S M , et al . Delivery of foreign antigens by engineered outer membrane vesicle vaccines [J ] . Proceedings of the National Academy of Sciences of the United States of America , 2010 , 107 ( 7 ): 3099 - 3104 .

HUANG W W , WANG S J , YAO Y F , et al . Employing Escherichia coli -derived outer membrane vesicles as an antigen delivery platform elicits protective immunity against Acinetobacter baumannii infection [J ] . Scientific Reports , 2016 , 6 : 37242 .

CHEN L X , VALENTINE J L , HUANG C J , et al . Outer membrane vesicles displaying engineered glycotopes elicit protective antibodies [J ] . Proceedings of the National Academy of Sciences of the United States of America , 2016 , 113 ( 26 ): E3609 - E3618 .

SUZUKI H , NOGUCHI T , OGAWA K , et al . Fusion of parvovirus B19 receptor-binding domain and pneumococcal surface protein A induces protective immunity against parvovirus B19 and Streptococcus pneumoniae [J ] . Vaccine , 2021 , 39 ( 36 ): 5146 - 5152 .

MURALINATH M , KUEHN M J , ROLAND K L , et al . Immunization with Salmonella enterica serovar typhimurium-derived outer membrane vesicles delivering the pneumococcal protein PspA confers protection against challenge with Streptococcus pneumoniae [J ] . Infection and Immunity , 2011 , 79 ( 2 ): 887 - 894 .

MATTHIAS K A , REVEILLE A , CONNOLLY K L , et al . Deletion of major porins from meningococcal outer membrane vesicle vaccines enhances reactivity against heterologous s erogroup B Neisseria meningitidis strains [J ] . Vaccine , 2020 , 38 ( 10 ): 2396 - 2405 .

GERRITZEN M J H , MAAS R H W , VAN DEN IJSSEL J , et al . High dissolved oxygen tension triggers outer membrane vesicle formation by Neisseria meningitidis [J ] . Microbial Cell Factories , 2018 , 17 ( 1 ): 157 .

ROSENBERG G , RIQUELME S , PRINCE A , et al . Immunometabolic crosstalk during bacterial infection [J ] . Nature Microbiology , 2022 , 7 ( 4 ): 497 - 507 .

EICHELBERGER K R , CASSAT J E . Metabolic ada ptations during Staphylococcus aureus and Candida albicans co-infection [J ] . Frontiers in Immunology , 2021 , 12 : 797550 .

PULENDRAN B , S ARUNACHALAM P , O′HAGAN D T . Emerging concepts in the science of vaccine adjuvants [J ] . Nature Reviews Drug Discovery , 2021 , 20 ( 6 ): 454 - 475 .

QIN S G , TANG X S , CHEN Y T , et al . mRNA-based therapeutics: powerful and versatile tools to combat diseases [J ] . Signal Transduction and Targeted Therapy , 2022 , 7 : 166 .

NGUYEN B , TOLIA N H . Protein-based antigen presentation platforms for nanoparticle vaccines [J ] . NPJ Vaccines , 2021 , 6 : 70 .

NAKAHASHI-OUCHIDA R , FUJIHASHI K , KURASHIMA Y , et al . Nasal vaccines: solutions for respiratory infectious diseases [J ] . Trends in Molecular Medicine , 2023 , 29 ( 2 ): 124 - 140 .

申赵铃 , 吴艳玲 , 应天雷 . 合成生物学与病毒疫苗研发 [J ] . 合成生物学 , 2023 , 4 ( 2 ): 333 - 346 .

SHEN Z L , WU Y L , YING T L . Synthetic biology and viral vaccine development [J ] . Synthetic Biology Journal , 2023 , 4 ( 2 ): 333 - 346 .

ZHAO W J . A forum on synthetic biology: meet the great challenges with new technology [J ] . National Science Review , 2021 , 8 ( 1 ): nwaa252 .

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

合成生物技术助力纳米颗粒疫苗理性设计时代的到来

合成生物学赋能细胞膜纳米颗粒的精准诊疗

合成生物学策略下的人工血液研究进展

合成生物学在医学诊疗中的应用与伦理治理：技术突破与价值边界

医用聚羟基脂肪酸酯（PHA）的生物合成策略及其在人类健康领域的新进展